NSC2450

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: NSC2450
• 英文别名: [2-(3,4-Dichlorophenyl)-4-quinolinyl](2-piperidinyl)methanol；[2-(3,4-dichlorophenyl)quinolin-4-yl]-piperidin-2-ylmethanol
• 化学式: C₂₁H₂₀Cl₂N₂O
• 分子量: 387.309
• InChiKey: NXTJDLLZXKYMMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  45.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  ethyl 2-(3,4-dichlorophenyl)quinoline-4-carboxylate 、 6-benzoylamino-hexanoic acid ethyl ester 生成 NSC2450
  参考文献：
  名称：

  α-(2-Piperidyl)-2-aryl-4-quinolinemethanols¹

  摘要：

  DOI：

  10.1021/ja01216a087

文献信息

• COMPOUNDS AND USE FOR TREATING CANCER
  申请人：GLIONOVA AB

  公开号：US20160214958A1

  公开（公告）日：2016-07-28

  The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.

  本发明涉及某些2,4-二取代喹啉衍生物及其治疗方法，以及包含该化合物的制药组合物。更具体地说，本发明涉及某些2,4-二取代喹啉衍生物或包含该化合物的制药组合物，用于治疗由过度活跃的Ras和/或Rac或信号通路所特征的癌症。
• REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER
  申请人：British Columbia Cancer Agency Branch

  公开号：EP2819662B1

  公开（公告）日：2019-04-10
• US9552457B2
  申请人：——

  公开号：US9552457B2

  公开（公告）日：2017-01-24
• [EN] EPIGENETIC REGULATORS AND USES THEREOF<br/>[FR] RÉGULATEURS ÉPIGÉNÉTIQUES ET UTILISATIONS ASSOCIÉES
  申请人：BRITISH COLUMBIA CANCER AGENCY

  公开号：WO2013059944A1

  公开（公告）日：2013-05-02

  Protein chromobox homolog 2 (CBX2) is provided as a target for the development of therapeutics for the treatment of diseases associated with a hyperactive polycomb 2 complex (PRC2), such as lymphomas, lung cancer, breast cancer, prostate cancer and cancers of the neurological system. Compounds of general Formula (I) suitable for use as therapeutics for the treatment of diseases associated with a hyperactive PRC2, for example, diseases characterized by hypermethylation activity of EZH2, are provided. Formula (I)
• [EN] REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER<br/>[FR] REPROGRAMMATION D'INTERACTIONS ENTRE PROTÉINES EFFECTRICES POUR CORRIGER DES DÉFAUTS ÉPIGÉNÉTIQUES DANS LE CANCER
  申请人：BRITISH COLUMBIA CANCER AGENCY

  公开号：WO2013127011A1

  公开（公告）日：2013-09-06

  Methods of "reprogramming" epigenetic mark readers or erasers to recognize epigenetic marks other than their cognate (or natural) marks are provided. Reprogramming the reader or eraser can offset the effects of aberrant writer activity (for example, loss of function or overactivity) that can contribute to certain diseases states, such as cancer. The use of the reprogramming compounds identified by these methods in the treatment of such disease states is also provided. Exemplary mark readers that can be targeted by these methods include BPTF and CBX2.